SGMO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sangamo Therapeutics Inc (SGMO) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. While the company has shown significant revenue growth in its latest quarter, the stock's technical indicators are bearish, and there are no strong positive catalysts or trading signals to suggest immediate upside potential. The options data and lack of recent news or significant insider activity further support a cautious approach.
The stock's technical indicators are bearish. The MACD is slightly positive but contracting, RSI is neutral at 37.882, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level at 0.249, with resistance at 0.267 and 0.286. The overall trend does not indicate a strong buying opportunity.
Revenue increased by 88.43% YoY in Q4 2025, showing strong growth. Gross margin remains at 100%, indicating operational efficiency.
No recent news, insider activity, or congress trading data to suggest a positive catalyst. Technical indicators and options data do not strongly support a bullish case.
In Q4 2025, revenue increased by 88.43% YoY to $14.23M. Net income improved by 59.94% YoY but remains negative at -$37.42M. EPS remains flat at -0.11. Gross margin is stable at 100%.
No recent analyst rating or price target changes are available for SGMO. Wall Street sentiment appears neutral, with no significant positive or negative views.
